Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Blueprint Medicines Corporation

Blueprint Medicines Corporation (BPMC) Stock Overview

Explore Blueprint Medicines Corporation’s financial performance, market position, analyst ratings, and future outlook.

BPMC●NASDAQ
HealthcareBiotechnology
$129.46
$0.18(0.14%)
U.S. Market is Open · 14:10

Blueprint Medicines Corporation (BPMC)

Meyka AI Score

Z

Key Financials

Market Cap8.4B
P/E Ratio-120.99
EPS (TTM)$-2.51
ROE-0.31%
Fundamental Analysis

AI Price Forecasts

1 MonthN/A
3 MonthsN/A
1 Year Target$94.82

BPMC Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Blueprint Medicines Corporation (NASDAQ: BPMC) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Blueprint Medicines Corporation's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of BPMC on the NASDAQ shows an RSI of N/A, suggesting the stock is in a an undetermined condition. Our forecasting models predict a 12-month price target of $94.82 for the NASDAQ listing.

Key metrics behind Blueprint Medicines Corporation's NASDAQ-traded stock include a P/E ratio of -120.99 and a market capitalization of 8.4B. Combined with our AI analysis, these give both institutional and retail investors a clear view of BPMC on the NASDAQ.

Price Performance (NASDAQ: BPMC)

1-Day Change
N/A
5-Day Change
N/A
1-Month Change
N/A
3-Month Change
27.31%
6-Month Change
39.99%
Year-to-Date (YTD) Change
48.46%
1-Year Change
35.28%
3-Year Change
111.64%
5-Year Change
71.29%
All-Time (Max) Change
586.06%

Contact Information

https://www.blueprintmedicines.com
617 374 7580
45 Sidney Street, Cambridge, MA, 02139

Company Facts

6,820 Employees
IPO DateApr 30, 2015
CountryUS

Frequently Asked Questions